411 related articles for article (PubMed ID: 24665023)
1. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B; Anderson M; Soussi T
Hum Mutat; 2014 Jun; 35(6):672-88. PubMed ID: 24665023
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Soussi T
Adv Cancer Res; 2011; 110():107-39. PubMed ID: 21704230
[TBL] [Abstract][Full Text] [Related]
3. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
4. Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm.
Soussi T
Hum Mutat; 2014 Jun; 35(6):643-53. PubMed ID: 24478183
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.
Soussi T; Leroy B; Taschner PE
Hum Mutat; 2014 Jun; 35(6):766-78. PubMed ID: 24729566
[TBL] [Abstract][Full Text] [Related]
6. The UMD-p53 database: new mutations and analysis tools.
Béroud C; Soussi T
Hum Mutat; 2003 Mar; 21(3):176-81. PubMed ID: 12619103
[TBL] [Abstract][Full Text] [Related]
7. The UMD TP53 database and website: update and revisions.
Hamroun D; Kato S; Ishioka C; Claustres M; Béroud C; Soussi T
Hum Mutat; 2006 Jan; 27(1):14-20. PubMed ID: 16278824
[TBL] [Abstract][Full Text] [Related]
8. MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.
Soussi T; Hamroun D; Hjortsberg L; Rubio-Nevado JM; Fournier JL; Béroud C
Hum Mutat; 2010 Sep; 31(9):1020-5. PubMed ID: 20572016
[TBL] [Abstract][Full Text] [Related]
9. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.
Soussi T; Kato S; Levy PP; Ishioka C
Hum Mutat; 2005 Jan; 25(1):6-17. PubMed ID: 15580553
[TBL] [Abstract][Full Text] [Related]
10. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
11. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
[TBL] [Abstract][Full Text] [Related]
13. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
14. Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
[TBL] [Abstract][Full Text] [Related]
15. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
16. Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
Donehower LA
Hum Mutat; 2014 Jun; 35(6):715-27. PubMed ID: 24415648
[TBL] [Abstract][Full Text] [Related]
17. The IARC TP53 database: new online mutation analysis and recommendations to users.
Olivier M; Eeles R; Hollstein M; Khan MA; Harris CC; Hainaut P
Hum Mutat; 2002 Jun; 19(6):607-14. PubMed ID: 12007217
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
19. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
20. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
